Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,312.93
  • Today's Change-19.07 / -1.43%
  • Shares traded14.10k
  • 1 Year change+67.25%
  • Beta0.6500
Data delayed at least 20 minutes, as of Jul 26 2021 14:34 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

  • Revenue in GBP (TTM)87.73m
  • Net income in GBP-6.25m
  • Incorporated1996
  • Employees673.00
  • Location
    Oxford BioMedica PLCWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
  • Phone+44 186 578 3000
  • Fax+44 186 578 3001
  • Websitehttp://www.oxfordbiomedica.co.uk
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Arix Bioscience PLC477.00k126.30m231.20m330.001.990.7293--484.690.88820.88820.00342.420.0018--0.38411,445.4646.78--47.52------26,478.20------0.0008---5.73--281.25------
Eco Animal Health Group Plc85.90m3.68m237.00m204.0068.042.8727.052.760.05140.05141.201.220.80122.173.52421,053.906.428.488.3310.2748.2547.208.0213.762.275.480.059662.007.2213.08-64.40-8.81-13.81--
Sareum Holdings Plc47.20k-926.91k248.16m6.00--177.80--5,257.73-0.0003-0.00030.000010.00040.0316--0.70987,866.67-62.02-48.02-71.74-51.95-----1,963.79-9,651.86---24.860.00------32.12------
Creo Medical Group PLC9.43m-20.32m299.35m217.00--4.68--31.75-0.1303-0.13030.06050.39780.10381.432.6043,451.06-22.35---26.24--42.79---215.46--2.46--0.1644--69,899.11---27.68------
Amryt Pharma Holdings Ltd135.48m-66.97m300.47m99.00--7.61--2.22-0.4051-0.40510.82270.2202-----------22.53---27.2241.0637.63-49.43-86.261.73-1.810.7831--214.17---65.92------
Synairgen plc0.00-13.92m307.87m18.00--3.62-----0.0986-0.09860.000.42590.00----0.00-30.05-30.56-31.80-33.63-------431.9325.86--0.0015-------258.20--50.02--
Avacta Group Plc3.64m-18.89m355.11m123.00--5.71--97.67-0.0901-0.09010.01760.24510.07597.201.4629,560.98-39.41---41.92--59.98---519.55--14.02-72.420.0319--------------
Alliance Pharma plc129.80m8.03m535.31m221.0068.211.9031.614.120.01470.01470.24160.52720.28332.445.15587,334.801.755.271.866.1163.8061.016.1816.871.808.990.335831.58-4.3021.84-67.90-8.76-49.067.92
Ergomed PLC86.39m9.68m563.86m1.01k60.3610.6838.826.530.19130.19131.711.081.16--4.4085,620.4112.960.609319.380.837745.9039.9311.210.5741--15.880.08810.0026.5723.4173.8644.2211.91--
Vectura Group PLC190.60m122.40m903.92m500.007.491.655.264.740.20160.20160.33390.91350.31853.161.57381,200.0020.46--23.37--53.20--64.22--
Puretech Health PLC8.55m4.35m987.10m66.00523.902.02121.18115.440.00660.00660.02951.700.0122--5.19129,553.200.47315.350.55547.07----38.82290.68----0.10490.0020.00-0.1017-98.58--3.31--
Oxford BioMedica plc87.73m-6.25m1.10bn673.00--9.73306.1012.54-0.0817-0.08171.101.370.57188.782.51130,353.60-4.07-8.50-5.54-11.4152.5254.07-7.12-14.241.93-2.850.1094--36.9540.7061.13---4.39--
Indivior PLC489.72m69.03m1.10bn819.0017.539.2213.542.250.08560.08560.61310.16270.43161.293.96597,950.806.085.1810.5412.0783.9887.5514.098.001.7912.330.63230.00-17.58-8.59-210.45---33.60--
Data as of Jul 26 2021. Currency figures normalised to Oxford BioMedica PLC's reporting currency: UK Pound GBX

Institutional shareholders

40.04%Per cent of shares held by top holders
HolderShares% Held
Vulpes Investment Management Pte Ltd.as of 09 Jun 20219.87m11.95%
M&G Investment Management Ltd.as of 15 Mar 20217.13m8.64%
Liontrust Investments Ltd.as of 02 Jul 20213.83m4.64%
Hargreaves Lansdown Asset Management Ltd.as of 15 Mar 20213.09m3.74%
Artisan Partners LPas of 15 Mar 20212.62m3.17%
Banque Pictet & Cie SAas of 02 Jul 20211.77m2.14%
UBS Asset Management Switzerland AGas of 02 Jul 20211.57m1.90%
Amati Global Investors Ltd.as of 02 Jul 20211.09m1.33%
BlackRock Investment Management (UK) Ltd.as of 02 Jul 20211.07m1.30%
Threadneedle Asset Management Ltd.as of 02 Jul 20211.03m1.24%
More ▼
Data from 31 Mar 2021 - 08 Jul 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.